Superbug That Can Feed on Plastic Is Spreading in Hospitals
A nasty bacterial superbug that kills hundreds of thousands of people per year is spreading through hospitals — and it feeds on something surprising, scientists have now found.
Researchers from the Brunel University of London have found, per a new study in the journal Cell, that the bacterial Pseudomonas aeruginosa appears to "digest" medical plastic.
Associated with more than 559,000 deaths globally per year, this drug-resistant bug is, according to the Center for Disease Control and Prevention, believed to cause other illnesses like pneumonia or urinary tract infections. People often seem to develop it after surgery, but until this study, researchers weren't aware that it might be living or feeding on medical plastics.
By analyzing a strain of the bacteria taken from a patient's wound swab, the microbial researchers found that P. aeruginosa seems specifically to survive longer on polycaprolactone, a plastic used in all kinds of medical interventions ranging from sutures, stints, and surgical mesh to wound dressings, drug-delivery patches, and implants.
In Brunel University's press release about the "world-first" research, study leader Ronan McCarthy said this finding suggests that medical professionals should rethink how bugs spread throughout hospitals and other healthcare settings.
"Plastics, including plastic surfaces, could potentially be food for these bacteria," McCarthy said. "Pathogens with this ability could survive for longer in the hospital environment."
The study also, as the professor noted, "means that any medical device or treatment that contains plastic" — including the ventilators some pneumonia patients need and catheters necessary for UTIs — "could be susceptible to degradation by bacteria."
Beyond its ability to break down such important medical tools, the researchers also found that the enzyme they isolated appears to grow stronger biofilms, or outer layers that help bacteria resist antibiotics and make them harder to treat, after digesting plastic.
Though there will obviously need to be more study to figure out how best to head off this plastic-eating menace, there's a 200-year history of pathogenic adaptation behind P. aeruginosa that suggests it may eventually circumvent any such measures.
Still, McCarthy pointed out that scientists "need to understand the impact this has on patient safety."
"Plastic is everywhere in modern medicine," he said, "and it turns out some pathogens have adapted to degrade it."
More on bacteria: Mysterious Bacteria Not Found on Earth Are Growing on China's Space Station
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Turners Falls family saved from carbon monoxide poisoning by alarm alert
TURNERS FALLS, Mass. (WWLP) – The Turners Falls Fire Department was sent to an alert of high levels of carbon monoxide in one family's home. Chicopee electrical fire prompts reminder of smoke detector importance The family was starting their morning as usual on Thursday when their carbon monoxide detector went off, alerting the residents to exit their home. They immediately called for emergency services, and after the Turners Falls Fire Department checked the home with a gas meter, dangerously high levels of carbon monoxide was found. The family's hot water boiler was running during a laundry cycle. Firefighters used specialized fans and isolated power to the boiler to ventilate the home. An issue with the flue/chimney was identified, and service professionals were contacted to help with repairs. No injuries were reported, and if you have any smoke or carbon monoxide detectors questions, call 413-863-9023. Carbon monoxide (CO) is an odorless, colorless gas that kills without warning, states the Center for Disease Control and Prevention (CDC). It claims the lives of hundreds of people every year and makes thousands more ill. Many household items including gas- and oil-burning furnaces, portable generators, and charcoal grills produce this poison gas. Working CO alarms are the only way to detect this invisible killer since we can not see, smell, or taste carbon monoxide. Check and test your CO alarms at the same time that you test and check your smoke alarms. These alarms are crucial home safety tools and should be installed on every level of your house and should be tested every month. It is important to put in fresh alkaline batteries if your alarms use them, and replace the alarms if they're more than 10 years old. Replace carbon monoxide alarms after five to seven years, depending on the specific model. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Associated Press
a day ago
- Associated Press
Engineered ion channel offers precise, non-invasive control of brain activity
FAYETTEVILLE, GA, UNITED STATES, May 30, 2025 / / -- In a breakthrough advancement for neuroscience, researchers have developed RADICAL, a cutting-edge chemogenetic tool that allows for the precise manipulation of neuronal activity using a synthetic chemical, cyclohexanol ( CHXOL ). Unlike traditional methods that rely on invasive optics or slow-acting G-protein coupled receptors, RADICAL utilizes a modified TRPM8 ion channel to enable rapid and targeted control of calcium influx in neurons. This innovative tool has the potential to advance brain function research and open up new therapeutic possibilities for neurological disorders. Current technologies for controlling neuronal activity—such as optogenetics and chemogenetics—have their limitations. Optogenetics requires invasive light delivery, while chemogenetic systems like DREADDs rely on slow and indirect cellular signaling pathways. Additionally, engineered ligand-gated ion channels, such as those based on nicotinic receptors, can result in unintended interactions with native proteins. These challenges have highlighted the need for a more efficient, non-invasive, and precise method of modulating neuronal excitability. In response to this gap, researchers sought to develop RADICAL, a novel chemogenetic tool that addresses these limitations. In a letter (DOI: 10.1093/procel/pwae048 ) published on September 3, 2024, in Protein & Cell, a team from Zhejiang University unveiled RADICAL, an engineered ion channel activated by cyclohexanol (CHXOL). By introducing specific mutations to the TRPM8 ion channel, they created a system that responds with exceptional sensitivity and specificity to CHXOL. This innovation allows for precise neuronal control without interfering with the brain's native functions, marking a significant step forward in chemogenetics. The key modification in RADICAL was the engineering of the TRPM8 ion channel, which is naturally expressed at low levels in the brain, minimizing potential disruptions to endogenous systems. The team introduced two critical mutations (I846F and I985K) to the TRPM8 ion channel. The I846F mutation restored CHXOL binding, while I985K enhanced voltage sensitivity, enabling robust activation even at hyperpolarizing potentials (-80 mV). Patch-clamp recordings and calcium imaging confirmed the double mutant, TRPM8-I846F-I985K's EC50 of 1.17 mmol/L for CHXOL at depolarizing potentials (+80 mV). In vivo, RADICAL demonstrated its potential: CHXOL administration enhanced fear extinction memory in mice by activating neurons in the infralimbic cortex (IL), and also increased locomotor activity when expressed in astrocytes of the ventral tegmental area (VTA). Importantly, the tool's calcium permeability and minimal cell death risk, as shown in HEK293T cells, suggest its suitability for studying calcium-dependent processes such as learning and memory. Dr. Fan Yang, one of the co-corresponding authors of the study, said: RADICAL represents a major breakthrough in chemogenetics. Its ability to modulate neuronal activity with high precision and minimal off-target effects makes it a versatile tool for both basic neuroscience research and the development of therapeutic interventions. With its non-invasive approach and high specificity, RADICAL has substantial potential in both research and clinical settings. It could enhance our understanding of neurological conditions such as memory disorders, addiction, and mood disorders by providing a precise way to manipulate neuronal circuits. Furthermore, future efforts to miniaturize the tool for adeno-associated virus (AAV) delivery could broaden its applicability in gene therapy. RADICAL's unique combination of speed, specificity, and safety positions it as a powerful platform for next-generation treatments of brain diseases. References DOI 10.1093/procel/pwae048 Original Source URL Funding Information This work was supported by funding from the National Natural Science Foundation of China (32122040 and 31971040 to F.Y.; 32071017 and 31922031 to Y.C.); Zhejiang Provincial Natural Science Foundation of China (LR20C050002 to F.Y.); China Postdoctoral Program for Innovative Talents (BX20230323 to H.Z.); China Postdoctoral Science Foundation (2024M752858 to H.Z.); The Fundamental Research Funds for the Central Universities (226-2022-00227 to F.Y.; 226-2022-00149 to Y.C.); Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions (NYKFKT2019001 to Y.C.); The Fundamental Research Funds for the Central Universities (226-2022-00227 to F.Y.). Lucy Wang BioDesign Research email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Politico
a day ago
- Politico
FDA denies ultra-rare drug but offers path to ‘yes'
Presented by With help from Chelsea Cirruzzo Driving The Day ANOTHER BLOW TO BARTH'S TREATMENT — The FDA rejected Stealth BioTherapeutics' latest bid to market its proposed treatment for an ultra-rare genetic condition, though regulators have suggested a 'path' toward accelerated approval, the company said Thursday. Stealth said the agency's complete response letter, which came four months after the FDA was initially scheduled to make a decision, didn't raise concerns with clinical safety data for the drug, known as elamipretide, to treat Barth syndrome by targeting underlying dysfunction in mitochondria, which are small energy-producing structures in cells. CEO Reenie McCarthy told Prescription Pulse that agency requests for additional data in late 2024 led the biotech to expect approval, and the biotech believes they should have gotten accelerated approval based on what the FDA conveyed in the letter. 'They have all the information they need to make that decision,' she said. HHS didn't respond to a request for comment. Background: Barth syndrome — which can cause an enlarged and weakened heart, muscle weakness, recurrent infections and delayed growth — typically affects males and shortens their life expectancy by decades. About 150 Americans have the condition. Stealth had suggested two ways the FDA could consider approving elamipretide — granting full approval based on the company's natural history study of disease progression absent medical intervention or endorsing accelerated approval based on a trial suggesting long-term improvements in muscle function. The FDA has agreed to consider muscle strength around the knees as a potential intermediate marker by which it could support accelerated approval and has asked Stealth to resubmit its application based on that endpoint, McCarthy said. External FDA advisers voted last year to recommend approval for elamipretide despite persistent questions about its effectiveness. Stealth, rare disease advocates and patients with Barth syndrome and their caregivers have advocated for years for FDA approval, highlighting the difficulties in conducting trials for potential rare disease treatments that can't be studied in large populations. Thursday's rejection seems 'inconsistent' with FDA Commissioner Marty Makary's recent comments about approving rare disease therapies based on plausible mechanisms and patient demand, McCarthy said. 'There's a bit of a disconnect' between those statements and the FDA's feedback, she said. What's next: Stealth expects to meet with the FDA next month to discuss a postmarketing study it proposed in 2022 and 'gauge how serious they are,' McCarthy said. The company laid off 30 percent of its staff to save money for a potential FDA resubmission and to maintain elamipretide access for critically ill patients under the agency's compassionate use pathway. McCarthy also raised concern about the FDA's stance that an accelerated approval would make the drug inappropriate to administer to newborns in acute cardiac distress, a population she said makes up two-thirds of Stealth's expanded access program. Half of early Barth syndrome deaths occur by age 1, per the company. IT'S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. Do you work at HHS? We want to learn more about the decision to cancel Moderna's bird flu vaccine funding. Send your tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA REPLACING COLOR ADDITIVES IN MEDS — The FDA quietly released draft recommendations for drugmakers that want to replace color additives in their approved drugs — potentially hinting at where the Trump administration will next focus HHS Secretary Robert F. Kennedy Jr.'s Make America Healthy Again energies. The agency acknowledged that changing the formulation of a drug — including its inactive ingredients — is generally considered a major change. But the agency said replacing a color additive with another already listed in the FDA's color-additive regulations in many cases 'is unlikely to have an adverse effect on the identity, strength, quality, purity, or potency of the drug product.' Replacing a color additive can 'generally be considered a moderate change' that can be requested via a 30-day supplement known as a CBE-30, according to the draft guidance published Thursday. 'If a manufacturer or an applicant intends to use a color additive that is not already listed in FDA's color additive regulations for the particular use, a petition must be sent to the Human Foods Program,' the draft guidance says. 'If FDA finds the color additive safe and suitable for such use, the additive will be listed in the color additive regulations.' What's next: The FDA is taking comments on the draft guidance for 60 days. AROUND THE AGENCIES LAYOFFS ON HOLD — CDC layoffs planned for early June are being paused in the wake of a preliminary injunction, two employees at the agency, granted anonymity for fear of retribution, confirmed to POLITICO's Sophie Gardner. CDC employees who were sent termination notices in April received an email from the agency's Office of Human Resources on Thursday, informing them that, because of a preliminary injunction, HHS 'is staying further action on any existing Reduction in Force (RIF) notices, including final separation of employees, at this time.' The laid-off employees will remain on paid administrative leave 'or in their current employment status' until further notice, the email said. An HHS spokesperson did not immediately respond to a request for comment. Background: On April 1, amid a massive restructuring of HHS, around 18 percent of the CDC's workforce received termination notices. But legal challenges have complicated the reduction in force and the HHS reorganization, meaning the vast majority of those employees are still technically employed at the CDC, with most remaining on administrative leave. Key context: On May 22, Judge Susan Illston of the federal district court in San Francisco issued a preliminary injunction that bars the administration from carrying out the reduction in force across 22 agencies — including HHS — that are defendants in the case. Federal employee unions, nonprofits and local governments are the plaintiffs. The email sent to CDC employees cites Illston's injunction as the reason for the decision. PROOFREADER WANTED — The White House blamed 'formatting issues' for errors in the citations of the recently released Make America Healthy Again report after a media report found studies in it that do not exist. 'We have complete confidence in [Secretary Robert F. Kennedy Jr.] and his team at HHS. I understand there were some formatting issues with the MAHA report,' White House press secretary Karoline Leavitt said Thursday. Her remarks came after NOTUS reported that seven of the sources cited in the report, which said children's health is in crisis and blamed chemicals, lack of exercise and ultraprocessed foods, don't exist. The report now lists five of its citations as 'corrected' or 'updated,' though that doesn't include the citations NOTUS reported as false. 'Some of the hundreds of citations in the report were formatted incorrectly or mistakenly referenced something other than what was actually intended,' a White House spokesperson told Pulse. 'That said, the content of the report is fully substantiated, and there is nothing in there that cannot be backed up; we did not conjure up any facts. Report has been corrected now.' Pharma Moves Laura Akowuah has joined Cooley as special counsel. She previously worked at the FDA for more than a decade in enforcement roles. Document Drawer The FDA approved Eton Pharmaceuticals' hydrocortisone oral solution Wednesday as a replacement therapy in patients ages 5 and older with adrenocortical insufficiency. WHAT WE'RE READING POLITICO's Erin Schumaker spoke with Dr. Wafik El-Deiry, a Brown University cancer researcher, about his campaign to lead the National Cancer Institute amid NIH funding cuts. Two pharmacy benefit managers filed lawsuits Thursday challenging a recently passed Arkansas law they say would force pharmacies across the state to close, Modern Healthcare's Hayley DeSilva writes. Texas lawmakers have sent legislation to Republican Gov. Greg Abbott's desk that would make it easier for parents to start the process of exempting their children from school vaccine mandates, The Associated Press' Jim Vertuno reports. Several House Republicans are raising concerns about broad pharmaceutical tariffs potentially being placed on the industry, POLITICO's Ari Hawkins reports.
